Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy

J Infect Dis. 2003 Jan 1;187(1):144-8. doi: 10.1086/345870. Epub 2002 Dec 13.

Abstract

Human immunodeficiency virus (HIV) type 1 DNA assay data were obtained at baseline from 111 HIV-1-positive subjects who were treated with nucleosides. Higher baseline DNA level, HIV-1 RNA level, and infectious titer were comparably associated with an increased hazard of disease progression (each P<.03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log(10) higher level, 3.99; 95% confidence interval, 1.44-11.09; P=.008).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Acquired Immunodeficiency Syndrome / mortality
  • Acquired Immunodeficiency Syndrome / virology
  • Adult
  • Anti-HIV Agents / therapeutic use*
  • CD4 Lymphocyte Count
  • DNA, Viral / analysis*
  • Didanosine / administration & dosage
  • Disease Progression
  • HIV-1 / genetics*
  • Humans
  • Multivariate Analysis
  • Prognosis
  • RNA, Viral / blood
  • Zalcitabine / administration & dosage
  • Zidovudine / therapeutic use

Substances

  • Anti-HIV Agents
  • DNA, Viral
  • RNA, Viral
  • Zidovudine
  • Zalcitabine
  • Didanosine